IRVINE, CA, and HERSTAL, BELGIUM – May 15, 2024 (GlobeNewswire) – Mdxhealth SA (Nasdaq: MDXH), a commercial-stage precision diagnostics company, today announced that Michael K. McGarrity, Chief Executive Officer, will participate in the following investor conferences in June 2024.
William Blair 44th Annual Growth Stock Conference
Presentation: Wednesday, June 5, at 5:00pm ET
Webcast: https://wsw.com/webcast/blair97/mdxh/1942906
Jefferies Global Healthcare Conference
Presentation: Thursday, June 6, at 1:30pm ET
Webcast: https://wsw.com/webcast/jeff302/mdxh/1846928
Live webcasts of the presentations will be accessible on the Investor page of mdxhealth’s website at https://mdxhealth.com/presentations-events/. Replays will be available for up to 60 days following each event.
About mdxhealth®
Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. The Company’s U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
For more information:
mdxhealth This email address is being protected from spambots. You need JavaScript enabled to view it. | |
LifeSci Advisors (IR & PR) US: +1 518-221-0106 This email address is being protected from spambots. You need JavaScript enabled to view it. |
NOTE: The mdxhealth logo, mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS and Monitor mdx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.
Last Trade: | US$4.04 |
Daily Change: | -0.26 -6.05 |
Daily Volume: | 126,388 |
Market Cap: | US$199.980M |
July 03, 2025 May 14, 2025 February 26, 2025 February 12, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load